Marksans Pharma Intrinsic Value
MARKSANS • Healthcare
Current Stock Price
₹170.00
Primary Intrinsic Value
₹190.96
Market Cap
₹765.0 Cr
+100.0%
Upside
Median Value
₹340.00
Value Range
₹56 - ₹425
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
MARKSANS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹190.96 | ₹152.77 - ₹229.15 | +12.3% | EPS: ₹8.68, Sector P/E: 22x |
| Book Value Method | asset | ₹425.00 | ₹382.50 - ₹467.50 | +150.0% | Book Value/Share: ₹553.11, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹340.00 | ₹306.00 - ₹374.00 | +100.0% | Revenue/Share: ₹659.56, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹340.00 | ₹306.00 - ₹374.00 | +100.0% | EBITDA: ₹664.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹405.86 | ₹324.69 - ₹487.03 | +138.7% | CF Growth: 3.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹55.55 | ₹49.99 - ₹61.11 | -67.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹134.11 | ₹120.70 - ₹147.52 | -21.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹340.00 | ₹306.00 - ₹374.00 | +100.0% | ROE: 15.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹328.67 | ₹295.80 - ₹361.54 | +93.3% | EPS: ₹8.68, BVPS: ₹553.11 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
MARKSANS Intrinsic Value Analysis
What is the intrinsic value of MARKSANS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Marksans Pharma (MARKSANS) is ₹340.00 (median value). With the current market price of ₹170.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹55.55 to ₹425.00, indicating ₹55.55 - ₹425.00.
Is MARKSANS undervalued or overvalued?
Based on our multi-method analysis, Marksans Pharma (MARKSANS) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.07 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Marksans Pharma
Additional stock information and data for MARKSANS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹207 Cr | ₹183 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹230 Cr | ₹160 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹237 Cr | ₹108 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹99 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹179 Cr | ₹157 Cr | Positive Free Cash Flow | 8/10 |